Hypera S.A. (BVMF: HYPE3)

Market Cap	12.97B
Revenue (ttm)	7.78B
Net Income (ttm)	1.57B
Shares Out	632.68M
EPS (ttm)	2.46
PE Ratio	8.32
Forward PE	8.58
Dividend	1.23 (6.01%)
Ex-Dividend Date	Sep 24, 2024

Volume	5,115,700
Open	20.77
Previous Close	20.71
Day's Range	20.46 - 20.79
52-Week Range	20.35 - 37.18
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 10,301
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: HYPE3

Financial Performance

In 2023, Hypera's revenue was 7.91 billion, an increase of 4.88% compared to the previous year's 7.55 billion. Earnings were 1.65 billion, a decrease of -2.87%.